Definitive Contract 75N93020C00012
Award Date 6/1/20
Potential Completion Date 7/31/22
Potential Value $300K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
CRYSTAL CITY, CA 90220, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
7
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed Similar Awards
- The prime contractor Molecular Express Inc. was awarded a $300,000 firm fixed price Small Business Innovation Research Program Phase I contract by the National Institutes of Health National Institute of Allergy and Infectious Diseases. Under this contract, the contractor will engineer novel HIV GP41 ectodomain antigens for incorporation into VESIVAX immunogenic formulations, in response to a solicitation seeking proposals aligned with NIH and CDC public health missions. This total small business...
- This is a $1,999,866.00 Firm Fixed Price definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Molecular Express, Inc. for the design and engineering of Vesivax HIV immunogen formulations. The contract is a Total Small Business set-aside as part of the Small Business Innovation Research (SBIR) Program Phase II. Molecular Express is a minority-owned, self-certified small disadvantaged business...
- This is a $599,983 firm fixed-price contract awarded by the Department of Health and Human Services' National Institutes of Health, National Institute of Allergy and Infectious Diseases to Molecular Express, Inc., a minority-owned small business, under the Small Business Innovation Research (SBIR) program. The objective of the contract is to develop an effective HIV vaccine by exploring co-delivery formulations of HIV antigens and adjuvants. This contract is part of the agency's "Evaluation...
- This SBIR Phase I contract from the National Institutes of Health's National Institute of Allergy and Infectious Diseases, valued at $299,961, was awarded to Molecular Express Inc. to identify a potential HIV antigen-conjugated vaccine formulation. The contractor will explore co-delivery of HIV antigens and adjuvant molecules, as requested in the NIH/CDC SBIR solicitation seeking proposals on alternatives to cell culture materials, various cancer-related technologies, opioid withdrawal...
- Molecular Express Inc. was awarded a $2.3 million definitive contract by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to evaluate different co-delivery methods of a model HIV antigen using the Vesivax liposomal platform. This contract was awarded under a Small Business Innovation Research solicitation issued jointly by NIH and the Centers for Disease Control and Prevention seeking proposals aligned with agency missions through innovative solutions...
- This award is for a Small Business Innovation Research (SBIR) contract with the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID), valued at $213,800. The contract was awarded to Molecular Express, Inc., a minority-owned small business focused on developing biomedical research and treatments for infectious diseases. The contract was awarded under SBIR Topic 061, "Mucosal Stimulatory Vesivax Vaccines Against Enteric Infections," with a...
- This is a federal contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the Department of Health and Human Services, to Molecular Express, Inc., a minority-owned small disadvantaged business. The contract, valued at $440,933.00, is a Small Business Innovation Research (SBIR) Program Phase I award under TOPIC 039 VACCINES AGAINST PATHOGENS WITH SMALL MARKET POTENTIAL. The purpose of the contract is the SELECTION OF VESIVAX VACCINE FOR WEST NILE...
- The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $569,807 definitive contract to Molecular Express Inc. to support the development of a vesivis immunosimilar formulation. The firm fixed price contract runs from August 2021 through July 2023 and will be performed in Crystal City, California. Designated as a total small business set aside, the award tasks Molecular Express with delivering products and...
- This contract, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Molecular Express, Inc., focuses on the development of the company's Vesivax TLR7 Formula, a therapeutic vaccine candidate targeting infectious diseases. The $2,999,352.00 Firm Fixed Price contract, which does not have a set-aside designation, runs through August 31, 2027. Molecular Express is a minority-owned, small disadvantaged business that has previously secured numerous SBIR contracts and...
- The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a $3,599,784.00 Firm Fixed Price contract to Molecular Express, Inc., a minority-owned, self-certified small disadvantaged business, for the DEVELOPMENT OF VESIVAX CO-ADJUVANT FORMULATION OF 2E151. This definitive contract does not have a set-aside designation and is scheduled for completion by September 29, 2028. Molecular Express, Inc. specializes in developing innovative drug formulations, therapeutics, and...